Archives
-
H-151, Ferroptosis, and STING-Independent Protection
2026-10-20
A 2026 study identified a second pharmacology for the STING inhibitor H-151: radical-trapping antioxidant activity that suppresses ferroptotic lipid peroxidation independently of STING. The findings connect cellular, biochemical, genetic, and murine renal ischemia–reperfusion evidence, while leaving important questions about marker specificity, pharmacological selectivity, and translation unresolved.
-
H-151, ML-210, and the Limits of Ferroptosis Evidence
2026-10-19
Yin et al. reported that H-151, a STING inhibitor, also protected diverse cell models from ferroptosis-associated injury through a mechanism that appeared independent of STING and involved radical-trapping antioxidant activity. ML-210 served as one of the study’s GPX4-inhibitor comparators, but the evidence does not establish that any commercial ML-210 formulation, including the APExBIO-listed material, was used or independently validated. The findings support a mechanistic model for H-151 while leaving important questions about specificity, pharmacology, and translation unresolved.
-
Amiloride HCl Dihydrate: Evidence Boundaries
2026-10-18
The supplied APExBIO product record identifies Amiloride HCl dihydrate under SKU B2268, but provides no description, mechanism statement, study data, or identity-matched research evidence. Accordingly, this overview distinguishes commercial product provenance from experimentally demonstrated pharmacology and does not infer efficacy, measurement performance, or applicability.
-
EPZ-6438 and EZH2 Inhibition in Cervical Cancer
2026-10-17
Evidence from a 2025 cervical-cancer study supports EPZ-6438 as a mechanistically plausible EZH2 inhibitor that altered proliferation, apoptosis, cell-cycle distribution, tumour-associated markers and HPV16 oncoprotein readouts in cultured cervical-cancer models. However, the evidence remains preclinical: the study did not establish direct H3K27me3 mediation, used limited model diversity, and reported only preliminary chorioallantoic-membrane validation with n = 1 tissue sample per condition. These findings support further mechanistic investigation, not claims of clinical efficacy or superiority to cisplatin.
-
EZ Cap™ CBEmax mRNA: Evidence and Scope
2026-10-16
APExBIO identifies R1044 as EZ Cap™ CBEmax mRNA (m1Ψ), a research-use cytosine base-editor mRNA. The available material supports catalog identity and a class-level interpretation of sequence-based cytosine-editing measurements, but provides no identity-matched study establishing activity, fidelity, kinetics, editing outcomes, or applicability in a particular biological model.
-
Recombinant Human IL-12: Evidence Boundaries
2026-10-16
APExBIO lists Recombinant Human IL-12 under SKU P1126, but the available product information does not provide a detailed molecular description, mechanism statement, assay validation, potency result, or identity-matched research study. The product listing therefore supports only a limited catalog-level identity claim, not conclusions about bioactivity, specificity, reproducibility, therapeutic relevance, or performance in a particular model.
-
H-151, Ferroptosis, and Renal IRI
2026-10-15
Yin et al. report that H-151, previously characterized as a STING inhibitor, also suppresses ferroptotic lipid peroxidation through a STING-independent radical-trapping activity. Cellular, genetic, chemical, and murine renal ischemia–reperfusion injury evidence supports a dual-mechanism model, although the findings remain preclinical and do not establish clinical efficacy or the performance of any particular commercial formulation.
-
When Context Changes What an EZH2 Result Means
2026-10-15
An evidence-focused editorial on how model choice, comparator, endpoint, and provenance shape the interpretation of EPZ-6438 findings in HPV-associated cervical cancer research.
-
H-151 Links STING Inhibition to Ferroptosis Control
2026-10-14
Yin and colleagues reported that H-151 protected cells and mice from ferroptotic and renal ischemia-reperfusion injury through two separable activities: inhibition of STING signaling and direct radical-trapping antioxidant activity. The findings are strongest as a mechanistic preclinical study, supported by multiple cell models, STING-deficient systems, chemical comparators, and renal injury readouts. They do not yet establish clinical utility, the dominant mechanism in vivo, or equivalence between the study material and any commercial formulation.
-
EZH2 Signaling in Resistant Melanoma
2026-10-14
A 2026 study in BRAFV600E-mutant A375 melanoma cells examined how resistance to eIF4F-complex inhibition is connected to ERK1/2, AKT1, and EZH2 signaling. Its findings support a context-dependent, preclinical rationale for combined pathway inhibition, but they do not establish that EPZ-6438 was used or demonstrate clinical benefit.
-
What the Chloroquine Commentary Shows—and Does Not
2026-10-13
The cited paper is a commentary on how prior antiviral evidence should inform interpretation of early chloroquine claims for COVID-19. It does not evaluate Entecavir, BMS200475, hepatitis B virus, or any HBV treatment outcome, so it cannot support conclusions about chronic hepatitis B infection therapy or lamivudine-resistant HBV treatment.
-
METTL16–SENP3–LTF and HCC Ferroptosis
2026-10-13
Wang et al. report a preclinical METTL16–SENP3–LTF pathway that links m6A regulation to iron handling and ferroptosis resistance in hepatocellular carcinoma. The evidence spans cellular, organoid, mouse-model and human-sample analyses, but it does not establish clinical efficacy or connect Berbamine hydrochloride to this pathway.
-
Viperin’s Dual Antiviral Mechanism
2026-10-12
A 2026 study proposes that viperin restricts porcine deltacoronavirus not only through ddhCTP-mediated RNA synthesis interruption, but also by binding viral nsp8 and disrupting replication-transcription complex assembly. The findings are mechanistically suggestive, yet their broader antiviral and therapeutic relevance remains un established.
-
Z-VAD-FMK and Evidence Gaps in Cell-Death Research
2026-10-12
A supplied 2026 study reports that isobavachalcone produces features associated with apoptosis and pyroptosis in anaplastic thyroid carcinoma models. The findings support a caspase-linked mechanism, but they do not establish a comparative advantage for Z-VAD-FMK, prove that both death programs are independently required, or demonstrate clinical relevance.
-
Sulfo-NHS-LC-Biotin: Product Overview
2026-10-10
Sulfo-NHS-LC-Biotin, also called sulfosuccinimidyl-6-(biotinamido) hexanoate, is described by APExBIO as a water-soluble reagent for covalent biotin labeling of primary amines. No matched research paper is available here, so performance and application claims remain un independently validated.